ADMA ADMA Biologics Inc

+0  (1%)
Previous Close 4.56
Open 4.63
Price To book 0.00
Market Cap 59.40M
Shares 12,886,000
Volume 6,081
Short Ratio 3.32
Av. Daily Volume 25,553

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued July 29 2016. Third-party manufacturing issues cited.
Primary Immune Deficiency Diseases

Latest News

  1. ETFs with exposure to ADMA Biologics, Inc. : April 20, 2017
  2. Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of ADMA Biologics, Inc. - ADMA
  3. ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  4. ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  5. ADMA Biologics Reports Year End 2016 Financial Results, Accomplishments and Upcoming Milestones
  6. ADMA Biologics Inc (ADMA): Does It Stack Up To Its Peers?
  7. ADMA: Incremental Progress on CMC Issue Resolution.
  8. ETF’s with exposure to ADMA Biologics, Inc. : September 21, 2016
  9. ADMA - Reviewing 2Q:16 Results; Waiting for Clarity on Resubmission Timeline
  10. ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 16, 2016
  11. INVESTOR NOTICE: Goldberg Law PC Announces an Investigation of Claims against ADMA Biologics, Inc. and Advises Investors with Losses to Contact the Firm
  12. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of ADMA Biologics, Inc.
  13. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ADMA Biologics, Inc. (ADMA)
  14. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA